TRI 50B

Drug Profile

TRI 50B

Alternative Names: TRI 50; TRI B50

Latest Information Update: 07 Apr 2004

Price : $50

At a glance

  • Originator Thrombosis Research Institute
  • Developer Thrombosis Research Institute; Trigen Ltd
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections
  • 18 Nov 2003 Discontinued - Clinical-Phase-Unknown for Thrombosis in Poland (IV)
  • 18 Nov 2003 Discontinued - Phase-I for Thrombosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top